Novavax, Inc. Presentations & Investor Relations material

Novavax, Inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a wide range of infectious diseases. Our recombinant nanoparticles and Matrix-MTM adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Product PipelineOur product pipeline targets a variety of infectious diseases with vaccine candidates currently in clinical development for respiratory syncytial virus ('RSV'), seasonal influenza, pandemic influenza, and Ebola virus ('EBOV'). We have additional preclinical-stage programs for a variety of infectious diseases. Corporate OverviewNovavax is headquartered in Gaithersburg, Maryland with additional facilities in Rockville, Maryland and Uppsala, Sweden. Novavax is traded on the Nasdaq Stock Market under the NVAX symbol and employs over 300 individuals dedicated to developing novel infectious disease vaccines.